Repository logo
 
Publication

Efficacy and safety of low-dose colchicine after myocardial infarction

2019-11-16Journal article Restricted access
Simple item page
dc.contributor.authorTardif, Jean-Claude
dc.contributor.authorKouz, Simon
dc.contributor.authorWaters, David D.
dc.contributor.authorBertrand, Olivier F.
dc.contributor.authorDiaz, Rafael
dc.contributor.authorMaggioni, Aldo P.
dc.contributor.authorPinto, Fausto J.
dc.contributor.authorIbrahim, Reda
dc.contributor.authorGamra, Habib
dc.contributor.authorKiwan, Ghassan S.
dc.contributor.authorBerry, Colin
dc.contributor.authorLópez-Sendón, José
dc.contributor.authorOstadal, Petr
dc.contributor.authorKoenig, Wolfgang
dc.contributor.authorAngoulvant, Denis
dc.contributor.authorGrégoire, Jean C.
dc.contributor.authorLavoie, Marc-André
dc.contributor.authorDubé, Marie-Pierre
dc.contributor.authorRhainds, David
dc.contributor.authorProvencher, Mylène
dc.contributor.authorBlondeau, Lucie
dc.contributor.authorOrfanos, Andreas
dc.contributor.authorL'Allier, Philippe L.
dc.contributor.authorGuertin, Marie-Claude
dc.contributor.authorRoubille, François
dc.date.accessioned2019-11-20T10:26:45Z
dc.date.available2019-11-20T10:26:45Z
dc.date.issued2019-11-16
dc.descriptionCopyright © 2019 Massachusetts Medical Society. All rights reserved.pt_PT
dc.description.abstractBackground: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. Methods: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. Results: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). Conclusions: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationN Engl J Med. 2019 Nov 16pt_PT
dc.identifier.doi10.1056/NEJMoa1912388pt_PT
dc.identifier.eissn1533-4406
dc.identifier.issn0028-4793
dc.identifier.urihttp://hdl.handle.net/10451/40198
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMassachusetts Medical Societypt_PT
dc.relation.publisherversionhttps://www.nejm.org/pt_PT
dc.titleEfficacy and safety of low-dose colchicine after myocardial infarctionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleNew England Journal of Medicinept_PT
person.familyNamePinto
person.givenNameFausto J.
person.identifier1308889
person.identifier.ciencia-idC311-AEDD-6DBB
person.identifier.orcid0000-0002-8034-4529
person.identifier.ridG-9363-2015
person.identifier.scopus-author-id7102740158
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication5f44176f-69f5-482c-83cd-ab94425a6ec3
relation.isAuthorOfPublication.latestForDiscovery5f44176f-69f5-482c-83cd-ab94425a6ec3

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Low_dose_colchicine.pdf
Size:
273.16 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FM-CCUL-Artigos em Revistas Internacionais